Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada's Price Negotiators On Where Firms Go Wrong

This article was originally published in Scrip

Executive Summary

If your company wants to sell its products on Canada's publicly funded drug plans, then it will likely have to do business with the pan-Canadian Pharmaceutical Alliance. This is the body that negotiates drug prices for provincial and territorial drug plans and which has ensured that product listing agreements have become a prerequisite for securing drug funding across the Canadian market. The pCPA's Brad Alyward, from Nova Scotia's Department for Health and Wellness, and Sherry O'Quinn*, from the Ontario Public Drug Programs Division, spoke to Scrip about the perils of trying to charge too high a price and the future of evidence generation-based agreements.

You may also be interested in...



Existential Crisis in Canada Could Lead To More Pricing Pressure

Worried about its relevance to payers, Canada's drug price regulator is consulting on how it should modernize its guidelines. The result could be more pressure on regulated prices.

UK Spinraza Data Review Shows Benefits Of NICE Flexibility

Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.

Can Artificial Intelligence Help With Market Access?

Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.

Topics

UsernamePublicRestriction

Register

SC064386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel